198 related articles for article (PubMed ID: 35360522)
1. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.
Costentin C; Piñero F; Degroote H; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Podestá LG; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Dibenedetto F; Duque SH; Salame E; Cillo U; Marciano S; Vanlemmens C; Fagiuoli S; Burra P; Van Vlierberghe H; Cherqui D; Lai Q; Silva M; Rubinstein F; Duvoux C;
JHEP Rep; 2022 May; 4(5):100445. PubMed ID: 35360522
[TBL] [Abstract][Full Text] [Related]
2. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
3. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
4. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
6. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
7. Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models.
Costentin CE; Amaddeo G; Decaens T; Boudjema K; Bachellier P; Muscari F; Salamé E; Bernard PH; Francoz C; Dharancy S; Vanlemmens C; Radenne S; Dumortier J; Hilleret MN; Chazouillères O; Pageaux GP; Calderaro J; Laurent A; Roudot-Thoraval F; Duvoux C;
Liver Int; 2017 May; 37(5):717-726. PubMed ID: 28199760
[TBL] [Abstract][Full Text] [Related]
8. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
Mehta N; Dodge JL; Roberts JP; Yao FY
Am J Transplant; 2018 May; 18(5):1206-1213. PubMed ID: 29068145
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.
Ng KT; Liu J; Yeung OW; Pang L; Shiu HC; Liu H; Yang XX; Chan AC; Wong TC; Lo CM; Man K
Hepatol Int; 2023 Dec; 17(6):1596-1609. PubMed ID: 37542605
[TBL] [Abstract][Full Text] [Related]
10. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels.
She WH; Chan ACY; Cheung TT; Lo CM; Chok KSH
World J Hepatol; 2018 Feb; 10(2):308-318. PubMed ID: 29527266
[TBL] [Abstract][Full Text] [Related]
12. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation.
Al-Ameri AAM; Wei X; Lin L; Shao Z; Guo H; Xie H; Zhou L; Zheng S; Xu X
BMC Cancer; 2019 Nov; 19(1):1136. PubMed ID: 31752756
[TBL] [Abstract][Full Text] [Related]
13. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.
Parfitt JR; Marotta P; Alghamdi M; Wall W; Khakhar A; Suskin NG; Quan D; McAllister V; Ghent C; Levstik M; McLean C; Chakrabarti S; Garcia B; Driman DK
Liver Transpl; 2007 Apr; 13(4):543-51. PubMed ID: 17394152
[TBL] [Abstract][Full Text] [Related]
14. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
15. Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria.
Lei Z; Li J; Wu D; Xia Y; Wang Q; Si A; Wang K; Wan X; Lau WY; Wu M; Shen F
JAMA Surg; 2016 Apr; 151(4):356-63. PubMed ID: 26579636
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America.
Piñero F; Tisi Baña M; de Ataide EC; Hoyos Duque S; Marciano S; Varón A; Anders M; Zerega A; Menéndez J; Zapata R; Muñoz L; Padilla Machaca M; Soza A; McCormack L; Poniachik J; Podestá LG; Gadano A; Boin IS; Duvoux C; Silva M;
Liver Int; 2016 Nov; 36(11):1657-1667. PubMed ID: 27169841
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
[TBL] [Abstract][Full Text] [Related]
19. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
20. Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study.
Piñero F; Costa P; Boteon YL; Duque SH; Marciano S; Anders M; Varón A; Zerega A; Poniachik J; Soza A; Machaca MP; Menéndez J; Zapata R; Vilatoba M; Muñoz L; Maraschio M; Fauda M; McCormack L; Gadano A; Boin IS; García JHP; Silva M
Ann Hepatol; 2018 Mar; 17(2):256-267. PubMed ID: 29469048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
